AI Terminal
Evonik Industries AG
Regulatory Filings • Apr 8, 2016
150_rns_2016-04-08_122ff590-e7b6-43fa-b9e6-5e73dfcc2e3c.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 8 April 2016 09:00
Evonik Industries AG: Evonik acquires French biotech company
DGAP-News: Evonik Industries AG / Key word(s): Takeover
2016-04-08 / 09:00
The issuer is solely responsible for the content of this announcement.
Evonik acquires French biotech company
– Evonik acquires strength in the area of sustainably developed ingredients for cosmetics
– Alkion Biopharma SAS extracts cosmetic actives from plant biomass
On April 6, 2016, Evonik Industries concluded a purchase agreement to take over the start-up Alkion Biopharma SAS, headquartered in Evry (France). The transaction is due to be completed in April. Alkion specializes in the development of biotechnological active ingredients for the cosmetics industry and was founded as a spin-off of the Imperial College London in 2011. Evonik is purchasing this company to expand the portfolio of the Personal Care Business Line in the area of active ingredients. The purchase price has not been disclosed.
“Thanks to its formulation and application expertise, Evonik enjoys an excellent reputation in the cosmetics industry. We are resolutely continuing along this path with the acquisition of Alkion,” said Dr. Tammo Boinowitz, head of the Personal Care Business Line at Evonik. By taking over the French biotech company, Evonik is strengthening its portfolio of specialty active ingredients. “This allows us to offer customers product concepts to set themselves apart from competitors,” said Boinowitz. Evonik is now able to offer its customers highly effective customized plant-based active ingredients that live up to their product claims.
Alkion Biopharma SAS is one of the leading manufacturers of biotechnologically developed cosmetic active ingredients. The company has developed methods for cultivating plant biomass under laboratory conditions and obtaining extracts from this with an exceptionally high yield of complex ingredients. The entire process takes place without altering the plant genome. “We are simply reinforcing the strength of nature. This results in unique, innovative cosmetic actives,” said Dr. Franck Michoux, founder and CEO of Alkion. He believes the affiliation with Evonik will provide outstanding opportunities for successful marketing of this technology.
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015.
Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Contact:
| Tim Lange Head of Investor Relations Phone +49 201 177-3150 [email protected] |
| Evonik Industries AG Rellinghauser Straße 1-11 45128 Essen Germany Phone +49 201 177-01 Telefax +49 201 177-3475 www.evonik.com Supervisory Board Dr. Werner Müller, Chairman Executive Board Dr. Klaus Engel, Chairman Dr. Ralph Sven Kaufmann Christian Kullmann Thomas Wessel Ute Wolf Registered office Essen Registered court Essen local court Commercial registry B 19474 VAT ID no. DE 811160003 |
2016-04-08 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | [email protected] |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013, XS0911405784 |
| WKN: | EVNK01, A1TM7T |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX; Luxemburg |
| End of News | DGAP News Service |